Novartis Gleevec Gains Five Orphan Cancer Indications
Simultaneous approvals add a solid tumor cancer and four blood disorders to the targeted oncologic’s labeling, for a total of seven indications in five years.
Simultaneous approvals add a solid tumor cancer and four blood disorders to the targeted oncologic’s labeling, for a total of seven indications in five years.